+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID06590961

Safety and Dose Evaluation of UBX-303061 for Relapsed or Refractory B-Cell Malignancies in an Open-Label Phase 1a1b Study

Led by Ubix Therapeutics, Inc. · Updated on 2026-10-21

94

Participants Needed

11

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating UBX-303061, an oral drug, in a first-in-human Phase 1a1b study involving patients with relapsed or refractory B-cell malignancies. This open-label, multicenter trial aims to assess the safety and potential anti-cancer effects of UBX-303061 in individuals who have received at least two prior therapies or have no other treatment options available. The study focuses on various B-cell cancers such as CLLSLL, DLBCL, FL, MCL, WM, and MZL. Participants will receive UBX-303061 orally during dose-escalation Phase 1a and dose-expansion Phase 1b parts of the study. The trial is designed to determine the maximum tolerated dose and recommended dose for further study. Dosing and treatment duration may last up to nine months. The study will also evaluate pharmacokinetics and pharmacodynamics of the drug, including measurements like Cmin, Cmax, tmax, and AUC. Throughout the study, participants will be monitored closely for dose-limiting toxicities, dose interruptions or reductions, and anti-tumor responses based on best overall response criteria. Genetic markers such as BTK, PLCG2, and MYD88 will be assessed. Safety and efficacy data will be collected up to the end of treatment, which may last up to nine months. The trial is sponsored by Ubix Therapeutics, Inc. and is planned to complete by August 2027.

CONDITIONS

Brief Title

UBX-303061 in Subjects With Relapsed/Refractory B-Cell Malignancies

Research Team

P

Project Manager

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here